Chronic cough is globally prevalent across all age groups. This disorder is challenging to
treat because many pulmonary and extrapulmonary conditions can present with chronic …

Chronic cough is defined in adults as a cough that lasts for≥ 8 weeks. When it proves
intractable to standard-of-care treatment, it can be referred to as refractory chronic cough …

Background Gefapixant is an oral P2X 3 receptor antagonist that has previously shown
efficacy and safety in refractory chronic cough and unexplained chronic cough. We therefore …

These guidelines incorporate the recent advances in chronic cough pathophysiology,
diagnosis and treatment. The concept of cough hypersensitivity has allowed an umbrella …

Background Gefapixant is a P2X3 receptor antagonist that has shown promise for the
treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate …

Background ATP acting via P2X3 receptors is an important mediator of refractory chronic
cough (RCC). This phase 2a double-blinded crossover study assessed the safety …

Background Chronic cough is a common complaint but there are little population-based data
on its burden in the United States. Objective To determine the prevalence of chronic cough …

Introduction: Patients with chronic cough experience considerable burden. The cough
severity visual analog scale (VAS) records patients' assessment of cough severity on a 100 …

We evaluated the effect of gefapixant on cough reflex sensitivity to evoked tussive challenge.
In this phase 2, double-blind, two-period study, patients with chronic cough (CC) and healthy …

Importance Gefapixant represents an emerging therapy for patients with refractory or
unexplained chronic cough. Objective To evaluate the efficacy and tolerability of gefapixant …